Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.44 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30902192 | 1.00 | MAP4K4 (0.48) | MAP4K4MEN1KMT2AGPR119SMARCA2 | |
| SCHEMBL30902260 | 0.84 | MAP4K4 (0.62) | MAP4K4MEN1KMT2ACNR1CNR2 | |
| SCHEMBL31029670 | 0.84 | MAP4K4 (0.62) | MAP4K4MEN1KMT2ACNR1CNR2 | |
| SCHEMBL30734207 | 0.78 | PIK3CD (0.46) | GPR119SMARCA2SMARCA4PBRM1PIK3CD | |
| SCHEMBL30902197 | 0.78 | PIK3CD (0.46) | GPR119SMARCA2SMARCA4PBRM1PIK3CD | |
| SCHEMBL28895326 | 0.78 | MEN1 (0.61) | MAP4K4MEN1KMT2AGPR119CNR1 | |
| SCHEMBL29002882 | 0.78 | MEN1 (0.61) | MAP4K4MEN1KMT2AGPR119CNR1 | |
| SCHEMBL23640794 | 0.77 | SMARCA2 (0.43) | MEN1KMT2AGPR119SMARCA2SMARCA4 | |
| SCHEMBL30902201 | 0.77 | MAP4K4 (0.48) | MAP4K4MEN1KMT2ACNR1CNR2 | |
| SCHEMBL31029618 | 0.77 | MAP4K4 (0.48) | MAP4K4MEN1KMT2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4406948-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | KRAS, NRAS, BRAF | MAP4K4 253/4885MEN1 357/4885KMT2A 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.